Compare DexCom, Inc. (DXCM) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JPMorgan Equity Premium Income ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B). The key difference: JPMorgan Equity Premium Income ETF is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and JPMorgan Equity Premium Income ETF for 57 Days on average.
| DXCM | JEPI | |
|---|---|---|
Market Cap | $31.86B | $45.55B |
Volume | 3,607,070 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $92.34 | $59.88 |
52-Week Low | $54.84 | $55.29 |
Typical Hold Time | 62 Days | 57 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
JEPI trades at $56.77, up 0.57% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend payments with recent distributions of $0.34-$0.37, positioning it as an income-focused vehicle. Recent news highlights JEPI's role in retirement income strategies and its appeal to investors seeking monthly distributions from covered call strategies.
The outlook remains cautious given the bearish technical setup, though the income generation capability provides downside cushion. Key risks include market volatility impacting the covered call strategy and interest rate sensitivity. Institutional interest continues with recent position increases, supporting the ETF's income-oriented appeal in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
